← Back to Search

Wearable Biosensor Accuracy for Alcohol Intoxication

N/A
Recruiting
Led By Catharine Fairbairn, PhD
Research Sponsored by University of Illinois at Urbana-Champaign
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up across the 14 day period of the study
Awards & highlights
No Placebo-Only Group

Summary

This trial will track participants' alcohol use over 14 days with sensors and breathalyzers, and involve 3 lab sessions to assess alcohol dose/rate of consumption.

Who is the study for?
This trial is for individuals who are at least 21 years old and drink alcohol at least twice a week. It's not suitable for those with medical or psychological conditions that make drinking unsafe, people currently treating an alcohol use disorder, pregnant women, or anyone taking medications that interact badly with alcohol.
What is being tested?
The study tests the accuracy of new wearable biosensors in measuring blood alcohol content (BAC). Participants will wear these sensors over two weeks while providing breathalyzer data during real-world drinking and controlled lab sessions where their drinking amounts vary.
What are the potential side effects?
Since the intervention involves consuming alcohol, potential side effects include typical reactions to intoxication such as impaired coordination, dizziness, nausea, vomiting, hangovers, and in severe cases acute alcohol poisoning.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~across the 14 day period of the study
This trial's timeline: 3 weeks for screening, Varies for treatment, and across the 14 day period of the study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Transdermal estimates of alcohol consumption
Transdermal estimates of blood alcohol concentration
Transdermal estimates of drinking risk level

Side effects data

From 2017 Phase 2 trial • 17 Patients • NCT01779024
59%
Increased Appetite
41%
Somnolence
35%
Euphoric mood
29%
Fatigue
12%
Hyperhidrosis
12%
Memory impairment
12%
Dizziness
12%
Nausea
6%
Feeling hot
6%
Flushing
6%
Headache
6%
Decreased appetite
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ghrelin
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Slow ConditionExperimental Treatment1 Intervention
Participants randomized to consume study beverages at a comparatively slow rate.
Group II: Fast ConditionExperimental Treatment1 Intervention
Participants randomized to consume study beverages at a comparatively rapid rate.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alcohol
2008
Completed Phase 3
~1990

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,392 Total Patients Enrolled
University of Illinois at Urbana-ChampaignLead Sponsor
197 Previous Clinical Trials
38,035 Total Patients Enrolled
Catharine Fairbairn, PhDPrincipal InvestigatorUniversity of Illinois Urbana-Champaign

Media Library

Fast Condition Clinical Trial Eligibility Overview. Trial Name: NCT05692830 — N/A
Alcohol Consumption Research Study Groups: Fast Condition, Slow Condition
Alcohol Consumption Clinical Trial 2023: Fast Condition Highlights & Side Effects. Trial Name: NCT05692830 — N/A
Fast Condition 2023 Treatment Timeline for Medical Study. Trial Name: NCT05692830 — N/A
~99 spots leftby Aug 2026